{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Drug+Interaction+%28DDI%29&page=2", "query": { "condition": "Drug Drug Interaction (DDI)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Drug+Interaction+%28DDI%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T11:22:12.828Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05202145", "title": "Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ALXN2050", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 61, "start_date": "2022-01-11", "completion_date": "2022-03-21", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05202145" }, { "nct_id": "NCT01082263", "title": "Midazolam Drug-Drug Interaction Study With Lurasidone HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia Patients" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2008-10", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2011-09-08", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Culver City, California", "locations": [ { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082263" }, { "nct_id": "NCT04782076", "title": "A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Dabigatran", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2021-03-05", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04782076" }, { "nct_id": "NCT01082276", "title": "Rifampin Drug-Drug Interaction Study With Lurasidone HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male, Healthy Normal Subjects" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 20, "start_date": "2008-08", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2011-09-08", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082276" }, { "nct_id": "NCT06533280", "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Part A, C and D: VH3739937 500 mg", "type": "DRUG" }, { "name": "Part A: VH3739937 100 mg", "type": "DRUG" }, { "name": "Part A and C: Placebo", "type": "DRUG" }, { "name": "Part B: Treatment A", "type": "DRUG" }, { "name": "Part B: Treatment B", "type": "DRUG" }, { "name": "Part B: Treatment C", "type": "DRUG" }, { "name": "Part B: Treatment D", "type": "DRUG" }, { "name": "Part B: Treatment E", "type": "DRUG" }, { "name": "Part D: Probe cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-08-02", "completion_date": "2024-08-14", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533280" }, { "nct_id": "NCT04845646", "title": "DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "NAFLD" ], "interventions": [ { "name": "ASC41", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gannex Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2021-03-16", "completion_date": "2021-06-10", "has_results": false, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04845646" }, { "nct_id": "NCT00000954", "title": "A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Zalcitabine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 72, "start_date": null, "completion_date": "1996-09", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000954" }, { "nct_id": "NCT01597310", "title": "Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "Dexpramipexole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Knopp Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2012-05", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2014-11-25", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597310" }, { "nct_id": "NCT06847464", "title": "A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "RSV Infection", "Drug Drug Interaction (DDI)" ], "interventions": [ { "name": "EDP-323", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "carbamazepine", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" }, { "name": "fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enanta Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2025-01-27", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06847464" }, { "nct_id": "NCT01074073", "title": "Lithium Drug-Drug Interaction Study With Lurasidone HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2008-08", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2011-09-08", "last_synced_at": "2026-06-11T11:22:12.828Z", "location_count": 1, "location_summary": "Culver City, California", "locations": [ { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074073" } ] }